Your welcome.
The point you make about first to market is extremely well made.
There is a thread somewhere dealing with this huge advantage covering anecdotal and academic research proving the point.
The trolls luxuriate from time to time in denying this reality of the real world and claiming if Intel wanted too they could have a neuromorphic chip tomorrow and swamp Brainchip. LOL
At the end of February Brainchip will have had its commercial AKD1000 for six months and the commercial IP in the market for 16 months.
What this means is that where the IP is concerned Brainchip already has the academically proven advantage of 12 months or more market lead and Renesas and MegaChip at least to its credit.
In August, 2022 AKD1000 will tick over a twelve month market lead and be at the point of greatest opportunity to defeat all new comers thereafter.
Only the ignorant and nefarious will continue to deny Brainchip’s achievements.
2022, 2022, 2022.
My anonymous opinion only even though the facts are irresistible and the market lead now virtually unassailable so still DYOR
FF
AKIDA BALLISTA
- Forums
- ASX - By Stock
- BRN
- 2021 BRN Discussion
2021 BRN Discussion, page-33312
-
-
- There are more pages in this discussion • 269 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BRN (ASX) to my watchlist
(20min delay)
|
|||||
Last
19.8¢ |
Change
-0.003(1.25%) |
Mkt cap ! $366.5M |
Open | High | Low | Value | Volume |
20.0¢ | 20.5¢ | 19.5¢ | $760.2K | 3.767M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
86 | 1429521 | 19.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.0¢ | 698108 | 26 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
85 | 1429408 | 0.195 |
61 | 1594021 | 0.190 |
31 | 1283131 | 0.185 |
53 | 1543743 | 0.180 |
17 | 632162 | 0.175 |
Price($) | Vol. | No. |
---|---|---|
0.200 | 728108 | 27 |
0.205 | 954646 | 21 |
0.210 | 1432297 | 27 |
0.215 | 536730 | 24 |
0.220 | 758461 | 24 |
Last trade - 14.39pm 15/07/2024 (20 minute delay) ? |
Featured News
BRN (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online